Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars - 2Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- 3RSF attack on Sudan’s South Kordofan kills at least 14, including children
- 4What are parents to do as doctors clash with Trump administration over vaccines?
- 5Russian billionaire says 12-hour days and 6-day workweeks could help save the economy
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Countdown to Artemis II: What to know about NASA's moon mission
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- Figure out How to Explore Land Close to 5G Pinnacles
- Manual for Tracking down the Mysterious Cascades in China
- Germany's Bundestag extends two armed forces missions abroad
